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Abstract  33 
Background:  34 
The risk of unexplained fetal death or stillbirth increases late in pregnancy suggesting that 35 
placental aging is an etiological factor. Aging is associated with oxidative damage to DNA, 36 
RNA and lipids. We hypothesized that placentas at more than 41 completed weeks of 37 
gestation (late-term) would show changes consistent with aging that would also be present in 38 
placentas associated with stillbirths. 39 
Objective:  40 
We sought to determine whether placentas from late-term pregnancies and unexplained 41 
stillbirth show oxidative damage and other biochemical signs of aging. We also aimed to 42 
develop an in vitro term placental explant culture model to test the aging pathways. 43 
Study design: 44 
We collected placentas from women at 37-39 weeks gestation (early-term and term), late-term 45 
and with unexplained stillbirth. We used immunohistochemistry to compare the three groups 46 
for: DNA/RNA oxidation (8-hydroxy-deoxyguanosine, 8OHdG), lysosomal distribution 47 
(Lysosome-associated membrane protein 2, LAMP2), lipid oxidation (4-hydroxynonenal, 48 
4HNE), and autophagosome size (Microtubule-associated proteins 1A/1B light chain 3B, 49 
LC3B). The expression of aldehyde oxidase 1 (AOX1) was measured by real-time PCR. 50 
Using a placental explant culture model, we tested the hypothesis that AOX1 mediates 51 
oxidative damage to lipids in the placenta. 52 
Results: 53 
Placentas from late-term pregnancies show increased AOX1 expression, oxidation of 54 
DNA/RNA and lipid, perinuclear location of lysosomes and larger autophagosomes compared 55 
to placentas from women delivered at 37-39 weeks. Stillbirth associated placentas showed 56 
similar changes in oxidation of DNA/RNA and lipid, lysosomal location and autophagosome 57 
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size to placentas from late-term. Placental explants from term deliveries cultured in serum 58 
free medium also showed evidence of oxidation of lipid, perinuclear lysosomes and larger 59 
autophagosomes, changes that were blocked by the G protein-coupled estrogen receptor 1 60 
(GPER1) agonist G1, while the oxidation of lipid was blocked by the AOX1 inhibitor 61 
raloxifene.  62 
Conclusions:  63 
Our data are consistent with a role for AOX1 and GPER1 in mediating aging of the placenta 64 
that may contribute to stillbirth. The placenta is a tractable model of aging in human tissue. 65 
 66 
Key words: placenta; aging; stillbirth; fetal death; autophagosome; DNA / RNA oxidation; 67 
lipid oxidation; AOX1; GPER1; raloxifene; placental explant culture 68 
 69 
Glossary of Terms 70 
Aldehyde Oxidase 1(AOX1) — an oxidizing enzyme with a wide range of substrates, that 71 
generates peroxides 72 
Autophagosome — an intracellular organelle that collects damaged proteins and old 73 
mitochondria 74 
G protein-coupled estrogen receptor 1 (GPER1) — a cell surface estrogen receptor distinct 75 
from nuclear estrogen receptors 76 
8-hydroxy-deoxyguanosine (8OHdG) — a product of DNA oxidation 77 
4-hydroxynonenal (4HNE) — a product of lipid peroxidation 78 
Lipid peroxidation — the oxidative degradation of lipids 79 
Lysosome — an intracellular organelle that contains proteolytic enzymes in an acid 80 
environment  81 
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Introduction 82 
Unexplained fetal death is a common complication of pregnancy occurring in approximately 1 83 
in 200 pregnancies in developed countries1 and more frequently in the developing world. 84 
While no cause has been established, the rate of fetal death rises rapidly as gestation 85 
progresses beyond 38 weeks2. Johnson et al.3 have proposed the operational definition of 86 
aging as an increase in risk of mortality with time, which is consistent with a role for aging in 87 
the etiology of stillbirth4.  Supporting this view a histopathological study of placentas 88 
associated with cases of unexplained intrauterine death at term revealed that 91% showed 89 
thickening of the maternal spiral artery walls, 54% contained placental infarcts, 10% had 90 
calcified areas and 13% demonstrated vascular occlusion5, another reported increased 91 
atherosclerosis6; changes that are associated with aging in other organs. Supporting a link 92 
between placental aging and stillbirth, Ferrari at al., have recently reported that telomere 93 
length is reduced in placentas associated with stillbirth7. Fetal growth restriction is also 94 
associated with both stillbirth and telomere shortening8. We therefore sought to determine 95 
whether placentas from women who delivered after 41 completed weeks (late-term) or had 96 
stillbirth had biochemical evidence of aging. As markers of aging we chose to measure 8-97 
hydroxy-deoxyguanosine (a marker of DNA oxidation) and 4-hydroxynonenal (a marker of 98 
lipid oxidation) as both have been described to increase in the brain with aging, and the 99 
enzyme aldehyde oxidase which is known to generate oxidative damage in the kidney. Aging 100 
is also known to affect the effectiveness of the intracellular recycling process that involves 101 
fusion of acidic hydrolase containing lysosomes with autophagosomes, we therefore sought 102 
changes in these intracellular organelles in the late-term placentas and those associated with 103 
stillbirth. 104 
 105 
Materials and Methods 106 
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Ethics, Collection and Processing of Tissues 107 
This study was approved by the human research ethics committee of the Hunter New England 108 
Health Services and the University of Newcastle, NSW, Australia. Human placentas were 109 
collected after written informed consent was obtained from the patients by midwives. 110 
Placentas were collected from women at 37-39 weeks gestation undergoing caesarean section 111 
for previous caesarean section or normal vaginal delivery, women at 41+ weeks gestation 112 
undergoing caesarean section or normal vaginal delivery, and women who had stillborn 113 
infants undergoing vaginal delivery.  Placentas were collected immediately after delivery and 114 
processed without further delay. Villous tissues were sampled from multiple sites and 115 
prepared for histology and RNA extraction. For each placenta, tissues were obtained from at 116 
least 5 different regions of the placenta and 4-5 mm beneath the chorionic plate. Samples 117 
from each individual placenta were immediately frozen under liquid nitrogen and stored at -118 
80° C until subsequent experiments. For histology experiments, tissues were fixed in 2% 119 
formaldehyde for 24 h, stored in 50% ethanol at room temperature (RT) and embedded in 120 
paraffin. To create a placental roll a 2 cm strip of chorioamniotic membrane was cut from the 121 
periphery of the placenta keeping a small amount of placenta attached to the membrane. The 122 
strip was rolled around forceps leaving residual placenta at the centre of the cylindrical roll. 123 
The cylindrical roll was then cut perpendicular to the cylindrical axis to obtain 4 mm thick 124 
sections and fixed in formalin. Placentas from patients with infection, diabetes, pre-eclampsia, 125 
placenta praevia, intra-uterine growth restriction or abruption were excluded. 126 
 127 
Reagents and Antibodies 128 
Antibodies against LAMP2 and AOX1 were obtained from BD Biosciences (North Ryde, 129 
Australia) and Proteintech (Rosemont, USA), respectively. Antibody against LC3B and 130 
GPER1 were obtained from Novus Biologicals (Littleton, USA). Antibodies against 8OHdG 131 
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and 4HNE were purchased from Abcam (Melbourne, Australia). Dulbecco’s modified Eagle’s 132 
medium (DMEM), antibiotic-antimycotic (anti-anti), Nupage precast 12 well protein gel and 133 
prolong gold antifade mounting media with DAPI, Alexa conjugated secondary antibodies 134 
were obtained from Thermo Fisher Scientific Australia Pty (Scoresby, Australia).  The horse 135 
radish peroxide (HRP) conjugated secondary antibodies were purchased from Cell Signalling 136 
Technologies (Beverly, MA, USA). Fetal bovine serum was obtained from Bovogen 137 
Biologicals Pty Ltd (VIC, Australia). Protease inhibitor and phosphatase inhibitor were 138 
supplied by Roche (Castle Hill, Australia). Raloxifene was purchased from Sigma-Aldrich 139 
(Sydney, Australia) and G1 was supplied by Tocris-bioscience (Bristol, UK). The BCA 140 
protein assay kit was obtained from Thermo Fisher Scientific (Scoresby, Australia). All other 141 
chemicals were purchased from either Ajax Finechem Pty Ltd or Sigma-Aldrich (Sydney, 142 
Australia).  143 
 144 
Placental Explant Culture 145 
For in vitro experiments, human term placentas (all at 39 weeks of gestation) were obtained 146 
from women with normal singleton pregnancies without any symptoms of labour after an 147 
elective (a scheduled repeat) caesarean section. Placentas were collected immediately after 148 
delivery and prepared for explant culture. Villous tissues of placentas were randomly sampled 149 
from different regions of the placenta 4-5 mm beneath the chorionic plate. Tissues were 150 
washed several times with Dulbecco's phosphate-buffered saline (PBS) under sterile 151 
conditions to remove excess blood. Villous explants of ~2 mm3 were dissected and placed into 152 
100 mm culture dishes (30 pieces/dish) containing 25 ml of DMEM supplemented with 2 mM 153 
L-glutamine, 1% Na-pyruvate, 1% penicillin/streptomycin (100X) solution with the addition 154 
of 10% (v/v) fetal bovine serum (FBS) and cultured in a cell culture chamber at 37 °C 155 
temperature under 95% air (20% oxygen) and 5% CO2 for 24 h. At day 2, villous explants 156 
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were transferred to fresh 30 ml growth medium and incubated in a cell culture chamber for 90 157 
minutes and washed in DMEM without FBS (referred to as ‘serum-free medium’ or ‘growth 158 
factor deficient medium’). Next 6-7 pieces of villous tissue weighing approximately 400 mg 159 
were transferred to a culture dish (60 mm) containing 6 ml serum-free medium with or 160 
without the addition of pharmacological agents, for example, raloxifene (1 nM) or the GPER1 161 
agonist G1 (1 nM), for subsequent incubation for 24 h.  At the end of 24 h some tissues were 162 
fixed in 2% formaldehyde, subjected to routine histological processing and embedded in 163 
paraffin wax, and some tissues were immediately frozen in liquid nitrogen and stored at -80 164 
°C until subsequent experiments. For each placental explant culture, samples were also 165 
collected at time ‘0 (zero)’ h i.e., before incubation in serum free medium, and were formalin 166 
fixed and stored frozen at -80 °C until further experiments. 167 
 168 
Western Blotting 169 
The western blotting was performed as previously described9. Samples of placenta (1gm) 170 
were crushed under liquid nitrogen. Aliquots of 100 mg of placental tissues were 171 
homogenised in 1 ml of lysis buffer (PBS, 1% Triton-X-100, 0.1 % Brij-35, 1 X protease 172 
inhibitor, 1 X phosphatase inhibitor, pH 7.4). The protein concentration of each placental 173 
extract was measured using a BCA protein assay kit and 40 µg of placental extract was 174 
separated by electrophoresis in NuPage bis-tris precast 12 well gels for 50 mins at a constant 175 
200 V. Separated proteins were then transferred to nitrocellulose membrane using a Novex 176 
transfer system for 70 mins and blocked overnight at 4 °C with 1% bovine serum albumin 177 
(BSA) in tris buffered saline with 0.1 % tween-20 (TBST). The membranes were then 178 
incubated with primary antibody in 1% BSA in TBST for 2 hours at RT, then washed three 179 
times with TBST, followed by incubating with HRP conjugated secondary antibodies in 1% 180 
BSA in TBST for an hour. After three further washes with TBST, the immuno-reactive bands 181 
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were developed in Luminata reagent (Merck Millipore) and detected using an Intelligent Dark 182 
Box LAS-3000 Imager (Fuji Photo Film, Tokyo, Japan). 183 
 184 
Immunohistochemistry 185 
Fluorescent immunohistochemistry (IHC) was performed according to previously published 186 
methods9. Six µm paraffin placental sections were deparaffinised and hydrated, then heated 187 
with tris-EDTA buffer (pH 9) in a microwave oven for antigen retrieval. The sections were 188 
blocked with 1 % BSA in TBST for an hour at RT. The sections were incubated with primary 189 
antibodies overnight and washed three times with TBST, before incubation with Alexa-190 
conjugated secondary antibodies for 90 mins. The sections were mounted with prolong gold 191 
antifade mounting media with DAPI. The fluorescent photographs for Figures 2, 3, 4, 5, 6, 7, 192 
S1, S2 and S3 were taken on a Nikon eclipse 90i confocal microscope (Nikon Instruments 193 
Inc.). The fluorescent photographs for Figure 8 were taken on Nikon eclipse Ti fluorescence 194 
microscope (Nikon Instruments Inc.).  195 
 196 
RNA isolation and Real time PCR 197 
Placental tissues were crushed under liquid nitrogen. Approximately 100 mg of crushed 198 
placental tissues were homogenised in 2 ml of Trizol reagent (Life Technologies) with an 199 
Ultra Turrax homogenizer. Total RNA was extracted from the Trizol-extract by Direct-zol™ 200 
RNA MiniPrep (Zymo Research). The RNA was treated with DNAse and purified with a 201 
RNA Clean & Concentrator™-5 kit (Zymo Research). The RNA quality was checked by 202 
running the DNAse treated sample in agarose gel with ethidium bromide in 1X TAE buffer. 203 
The purified RNA was used to make cDNA using a SuperScript® III First-Strand Synthesis 204 
System kit (Life Technologies). The cDNA was used to run real time PCR by Taqman 205 
primers for aldehyde oxidase 1 (AOX1) (Life Technologies, Assay ID: Hs00154079_m1) and 206 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
Taqman gene expression master mix (Life Technologies) with an internal control of 18s 207 
ribosomal RNA (Life Technologies) to quantify mRNA for AOX1. We used a SyBr green 208 
master mix to quantify mRNA for G-protein coupled receptor 1 (GPER1) (Invitrogen, 209 
Forward primer 5’-CGTCCTGTGCACCTTCATGT-3’ Backward primer 5’-210 
AGCTCATCCAGGTGAGGAAGAA-3’) with respect to beta-actin as an internal control 211 
using an Applied Biosystem 7500 PCR system. 212 
 213 
Statistical analysis 214 
Sample numbers are shown in the legends to individual figures. The data in Figures 2, 4, 5, 6 215 
and 8 were analysed using the Mann-Whitney test (two way) and results are presented as 216 
scatter plots showing the median. The data in Figure 7, S2 and S3 were analysed using the 217 
Wilcoxon matched-pairs signed rank test and results are presented as mean showing the 218 
standard error of the mean (S.E.M.). All the p-values were calculated using the Graphpad 219 
Prism software (Version 7, Graph Pad Software Inc., San Diego, California). A p-value of 220 
≤0.05 was considered statistically significant. 221 
 222 
Results 223 
Subject characteristics 224 
Demographic and clinical characteristics of the study participants are reported in table 1. 225 
 226 
Relationship between stillbirth risk and length of gestation 227 
To illustrate the relationship between stillbirth risk and length of gestation we created a 228 
Kaplan Myer plot of the data on human gestational length in a population with relatively low 229 
levels of medical intervention from Omigbodun and Adewuyi10 and combined it with the data 230 
on risk of stillbirth per 1000 continuing pregnancies from Sutan et al.2 (Figure 1 reproduced 231 
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with permission4). The data illustrate that stillbirth is consistent with an aging etiology as 232 
defined by Johnson et al.3. 233 
 234 
DNA/RNA Oxidation 235 
 We sought evidence of placental DNA/RNA oxidation as measured by 8-hydroxy-236 
deoxyguanosine (8OHdG), as a marker of DNA/RNA oxidation that has previously been 237 
observed in aging tissues11 such as the brain in Alzheimer’s disease12. Immunohistochemistry 238 
(IHC) was performed for 8OHdG and the average intensity of 8OHdG staining in 239 
nuclei/frame demonstrated a significant increase in DNA/RNA oxidation in late-term and 240 
stillbirth associated placentas (Figure 2).  241 
 242 
Movement and clustering of lysosomes in late-term and stillbirth placentas 243 
Misfolded proteins and damaged mitochondria are normally recycled in autophagosomes in a 244 
process that involves autophagosome fusion with proteolytic enzyme containing lysosomes. 245 
Accumulation of abnormal protein is thought to play a role in aging particularly in the brain, 246 
for instance the accumulation of tau and amyloid protein in Alzheimer’s disease13, 14 and 247 
mutant huntin in Huntington’s disease15. In Huntington’s disease, the distribution of the 248 
lysosomes within neurones is altered with increased perinuclear accumulation of lysosomes16. 249 
We used a lysosomal marker, lysosome-associated membrane protein-2 (LAMP2) to analyse 250 
the distribution of lysosomes in the placenta by IHC. IHC showed lysosomes positioned on 251 
the apical surface of early-term placental syncytiotrophoblast (Figures 3A, 3D and 3E), 252 
whereas lysosomes relocated to the perinuclear and the basal surface in late-term and stillbirth 253 
placentas (Figures 3B, 3C, 3F and 3G).  254 
 255 
Lipid oxidation in placental tissue 256 
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The increase in DNA oxidation which we had demonstrated suggested free radical damage 257 
that might also lead to lipid peroxidation. Lipid peroxidation has been observed to increase in 258 
Alzheimer’s disease as measured by the formation of 4-hydroxynonenal (4HNE)17. We 259 
therefore performed IHC for 4HNE in late-term, stillbirth and 37-39 weeks placental tissue. 260 
This revealed a marked, statistically significant increase in 4HNE staining in late-term 261 
syncytiotrophoblast that we also observed in placentas associated with stillbirth shown in 262 
Figure 4 (A-D). 263 
 264 
Larger autophagosomes containing 4HNE occur in late-term and stillbirth associated 265 
placentas 266 
Inhibition of autophagosome function with failure of fusion with lysosomes leads to an 267 
increase in autophagosome size18, 19. This process leads to inhibition of overall autophagic 268 
function that is seen in  Alzheimer’s disease18, Danon’s disease19 and neurodegeneration20. We 269 
detected autophagosomes using IHC with an antibody against LC3B. We observed a 270 
significant increase in the size of autophagosomes (Figure 5D) in both late-term (Figure 5B) 271 
and stillbirth (Figure 5C) associated placentas compared to 37-39 week placentas (Figure 5A). 272 
Dual labelled fluorescence immunostaining showed that the larger autophagosomes of late-273 
term and stillbirth placentas contained 4HNE, a product of lipid peroxidation (Supplementary 274 
Figure S1). 275 
 276 
Role of aldehyde oxidase 1 (AOX1) in placental oxidative damage 277 
Aldehyde oxidase 1 (AOX1) is a molybdoflavoenzyme, which oxidises a range of aldehydes 278 
including 4HNE into corresponding acids and peroxides21. We provide evidence that AOX1 is 279 
involved in the generation of the increased 4HNE observed in late-term and stillbirth 280 
associated placentas using co-localisation. Dual labelled fluorescence IHC showed that AOX1 281 
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co-localises to 4HNE positive particles in late-term (Figure 6A-C) and stillbirth placentas 282 
(Figure 6D-F). Additionally real-time qPCR showed that late-term and stillbirth placentas 283 
expressed significantly higher mRNA for AOX1 than 37-39 week placentas (6G). These data 284 
support the concept that AOX1 plays a role in the oxidative damage that occurs in the late-285 
term and stillbirth associated placentas. 286 
 287 
Pharmacological inhibition of AOX1 using placental explant culture  288 
Our data provide clear evidence for increased lipid oxidation, disordered lysosome-289 
autophagosome interactions and increased AOX1 expression in the late-term and stillbirth 290 
placental syncytiotrophoblast. To determine if these events were causally linked we developed 291 
a placental explant culture system using term placental tissue cultured in serum-free (growth 292 
factor deficient) medium. IHC showed that serum deprivation significantly increased 293 
production of 4HNE at 24 h after incubation (Figure 7A-C, F and G). We also found a 294 
significant  increase in the size of autophagosomes (Supplementary Figure S2) and a change 295 
in lysosomal distribution to a perinuclear location after 24 h incubation in serum-free medium 296 
(Supplementary Figure S3). We sought to determine cause and effect relationships between 297 
the development of lipid oxidation observed when placental explants were cultured in the 298 
absence of serum, and AOX1. To achieve this we used a potent AOX1 inhibitor, raloxifene22 299 
and a GPER1 agonist, G1. We used the GPER1 agonist G1 as we had detected GPER1 300 
expression on the apical surface of syncytiotrophoblast (Figure 8A and B) and the GPER1 301 
agonist has been shown to inhibit production of 4HNE in the kidney23. Both raloxifene and 302 
G1 inhibited the production of 4HNE in the serum starved placental explants after 24 h of 303 
treatment (Figure 7D, E, F and G). G1 also prevented the changes in lysosomal distribution 304 
within the syncytiotrophoblast (Supplementary Figure S3). 305 
 306 
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Presence of the cell surface estrogen receptor GPER1 on the apical surface of the 307 
syncytiotrophoblast 308 
As the GPER1 agonist had evident effects in placental explant cultures we undertook 309 
characterisation of GPER1 expression in placental tissue. The expression of GPER1 in a 310 
section of placenta roll (described in the Method section) detected by fluorescent IHC showed 311 
that GPER1 in expressed in placental villi (Figure 8A), which at higher magnification (100X), 312 
was localised to the apical surface of placental villi (Figure 8B). Real time PCR for GPER1 313 
showed that placental villi have significantly higher expression of GPER1 than amnion, 314 
chorion or decidua (Figure 8C). Western-blot for GPER1 also confirmed higher protein levels 315 
of GPER1 in placental villous tissue than amnion, chorion or decidua (Figure 8D). The 316 
demonstration of GPER1 localisation on the apical surface of the syncytiotrophoblast 317 
indicates the plausibility of estrogen inhibition of AOX1 activity in the placenta. 318 
 319 
Comment 320 
Our data indicate that between 37-39 and 41 weeks of gestation dramatic changes occur in the 321 
biochemistry and physiology of the placenta. In particular there is increased oxidative damage 322 
to DNA/RNA and lipid, a change in position of lysosomes which accumulate at the 323 
perinuclear and basal surface of the syncytiotrophoblast, the formation of larger 324 
autophagosomes which are associated with oxidised lipid, and there is increased expression of 325 
the enzyme AOX1. The same changes are observed in placentas associated with stillbirth. 326 
Some of our results are semi-quantitative as this is the nature of western analysis, nevertheless 327 
the robustness of our results is supported by the use of multiple end points for aging, and the 328 
biological plausibility of the reported links. Further supporting our hypothesis, similar 329 
changes in oxidation of lipid, localisation of lysosomes and size of autophagosomes occurred 330 
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in placental explants deprived of growth factors, and these changes were blocked by 331 
inhibition of AOX1. 332 
 333 
Stillbirth occurs in approximately 1 in 200 pregnancies in developed countries1. The Lancet1 334 
and the BMJ24 have recently highlighted gaps in our knowledge of this condition. Stillbirth 335 
frequently occurs in the setting of fetal growth restriction and in this setting telomere 336 
shortening and oxidative damage have been observed in associated placentas25. The risk of 337 
stillbirth per 1000 continuing pregnancies rises dramatically after 38 weeks of gestation. We 338 
have suggested4 that stillbirths in late gestation are a consequence of placental aging. More 339 
than 90% of pregnancies have delivered by the end of the 40th week of gestation10, 340 
consequently changes that occur in the placenta in pregnancies that have gone past the usual 341 
term have little effect on population level infant survival, since most have already delivered. 342 
Such late gestation changes may exist in a kind of Medawar’s Shadow26 that allows 343 
deleterious genes to persist in the population if their damaging effects occur after 344 
reproduction, especially if the same genes exert positive actions earlier in pregnancy. This 345 
Medawar’s Shadow effect has been proposed to explain the high prevalence of Huntington’s 346 
disease that is associated with increased fertility in early life but disastrous neurological 347 
deterioration after reproduction has occurred27. Our immunofluorescence data show high 348 
levels of 8OHdG and 4HNE in late-term and stillbirth placentas supporting this postulated 349 
pathway to placental aging. Increases in oxidative damages to DNA and lipid have also been 350 
reported in Alzheimer’s disease17, 28. 351 
 352 
We have also seen marked accumulation of particles positive for the lysosomal marker 353 
LAMP2 in the perinuclear and basal side of the syncytiotrophoblast of late-term placentas and 354 
placentas associated with stillbirth. This phenomenon closely resembles ‘lysosomal 355 
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positioning’ which occurs in cells under nutritional stress29. Autophagy is an important 356 
cellular recycling process that involves fusion of acidic lysosomes with the autophagosomes. 357 
Our data show that stillbirth and late-term placentas contain larger autophagosomes than 37-358 
39 week placentas indicating inhibition of the autophagic process in these placentas. Our data 359 
further indicate that the autophagosomes are coated with oxidised lipid in the form of 4HNE 360 
which may play a role in the failure of lysosomal-autophagosome fusion. Such disturbances in 361 
the function of autophagosomes may lead to the accumulation of abnormal protein and 362 
deterioration in the function of the syncytiotrophoblast.  363 
 364 
Stillbirth is not restricted to the late-term setting and is known to be associated with cigarette 365 
smoking and growth restriction. It seems likely that smoking accelerates aging related 366 
pathways. Evidence for this is the finding that telomere length is reduced in the fetuses of 367 
women who actively smoke during pregnancy30, and similar changes are to be expected in the 368 
placentas of smokers. Down’s syndrome is associated with advanced aging or progeria31, 32 369 
and also with increased rates of stillbirth33, 34, raising the possibility that accelerated placental 370 
aging may play a part in stillbirth related to Down’s and some other congenital anomalies. 371 
Similarly placental abruption is associated with growth restriction, maternal smoking and 372 
stillbirth, and placental aging may play a part in this condition35, 36. 373 
 374 
We have used cultured term placental explants to interrogate the pathways leading to the lipid 375 
oxidation and disturbed autophagosome function. We measured production of 4HNE and the 376 
diameter of autophagosomes following serum depletion.  We observed a significant increase 377 
in 4HNE and a significant increase in autophagosome size suggesting inhibition of autophagy 378 
by oxidative damage as we had previous observed in the stillbirth and late-term placentas. 379 
Raloxifene a potent inhibitor of AOX1 has been shown to reduce oxidative damage in 380 
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endothelial cells37. We have demonstrated that the AOX1 inhibitor raloxifene is also able to 381 
block the oxidative damage to the lipid in placental explants. The role of AOX1 was 382 
confirmed using the GPER1 agonist G1 that has been shown to block AOX1 activation and 383 
reduce 4HNE in renal tissue23.  The G1 also blocked the changes in lysosomal positioning 384 
within the explants. We report the novel finding of the presence of the cell surface estrogen 385 
receptor GPER1 on the syncytiotrophoblast apical membrane, suggesting that this receptor 386 
may play a role in modulating oxidative damage within the placenta. It has been shown that 387 
urine from pregnant women carrying a fetus with post-maturity syndrome have lower 388 
estrogen:creatinine ratios than women carrying normal foetuses38. These data support the 389 
possibility that low estrogen concentrations may lead to loss of the cell surface estrogen 390 
receptor (GPER1) mediated inhibition of AOX1 and consequently placental oxidative damage 391 
and impaired function. 392 
 393 
The changes in the late-term placenta occur as the fetus continues to grow and to require 394 
additional supplies of nutrients. Post-maturity syndrome is a condition seen in post-dates 395 
infants who show evidence of late gestation failure of nutrition39. Normal human infants born 396 
at term have 12-14% body fat whereas post maturity syndrome is associated with the birth of 397 
a baby with severe wrinkling of the skin due to loss of subcutaneous fat. Post-maturity 398 
syndrome is rarely seen in modern obstetric practice where delivery is usually effected before 399 
42 weeks of gestation using induction of labour or caesarean section if labour has not 400 
occurred spontaneously. While none of the infants born to mothers in our study exhibited 401 
post-maturity syndrome, our data suggest that the physiological function of the placenta after 402 
41 completed weeks is showing evidence of decline that has many features in common with 403 
aging in other tissues. The known exponential increase in unexplained intrauterine death that 404 
occurs after 38 weeks of gestation may therefore be a consequence of aging of the placenta 405 
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and decreasing ability to adequately supply the increasing needs of the growing fetus. This 406 
knowledge may impact on obstetric practice to ensure infants are born before the placenta 407 
ages to the point of critical failure40. However, it is notable that not all placentas in our late-408 
term cohort exhibited evidence of aging and it is known that infants born later in gestation 409 
have lower rates of special school needs, with those born at 41 weeks having the lowest 410 
rates41. The conflicting pressures of late gestation increases in stillbirth and falling rates of 411 
intellectual disability make obstetric care at this time very challenging, diagnostics that can 412 
predict pregnancies at increased risk of stillbirth would be useful and some progress in their 413 
development has been made42. Our data also indicate that the placenta may provide a tractable 414 
model of aging in a human tissue that uniquely ages in a 9 month period of time. The results 415 
suggest that the rate of aging of the placenta varies in different pregnancies and raises the 416 
possibility that the rate of aging of the placenta may parallel the rate of aging of the associated 417 
fetus carrying the same genome. Our work identifies potential therapeutic targets such as 418 
AOX1, that may arrest the oxidative damage to placentas in pregnancies identified at high 419 
risk of stillbirth when extreme prematurity precludes delivery. Finally, our data raise the 420 
possibility that markers of placental oxidative damage and AOX1 mRNA may be released 421 
into maternal blood where they may have diagnostic value in predicting the fetus at risk for 422 
stillbirth.  423 
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List of Tables and Figures 547 
 548 
Table 1: Demographic and clinical characteristics of the study subjects. 549 
 550 
Figure Legends: 551 
 552 
Figure 1: Relationship between stillbirth and number of continuing pregnancies. Kaplan 553 
Myer plot of number of continuing pregnancies as a function of gestational age and plot of 554 
unexplained stillbirth per 1000 continuing pregnancies, data from Omigbodun and Adewuyi10 555 
and Sutan et al.2. Plot shows the increase in risk of stillbirth with time consistent with the 556 
operational definition of aging proposed by Johnson et al.3 and the relatively small number of 557 
pregnancies at risk of stillbirth by 41 weeks because of prior delivery. Reproduced with 558 
permission from Smith et al.,.4* 559 
 560 
Figure 2: DNA/RNA oxidation in late-term and stillbirth placentas. Confocal microscopy 561 
showed increased 8OHdG staining (red) in nuclei from late-term (B) and stillbirth placentas 562 
(C) compared to 37-39 week placentas (A). DAPI (blue) staining identifies the nuclei. The 563 
graph (D) illustrates that late-term and stillbirth placentas have increased intensity of nuclear 564 
8OHdG staining (p<0.0001 for late-term placentas, p=0.0005 for stillbirth placentas, Mann 565 
Whitney test) compared to 37-39 week placentas. In Figure 2D open circles and filled circles 566 
represent 37-39 week caesarean non-labouring placentas (n=10) and vaginal delivery 567 
labouring placentas (n=8) respectively, and open squares and filled squares represent late-term 568 
labouring caesarean placentas (n=5) and labouring vaginal delivery placentas (n=13) 569 
respectively, and filled triangles represent third trimester labouring vaginal delivery 570 
unexplained stillbirth placentas (n=4). Each point in the graph represents the average intensity 571 
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of 8OHdG of 60 nuclei in 6 images per placenta photographed at 100X magnification and 1.4 572 
optical resolution. Scale bar, 20 µm. The microscopy also indicates increased staining in the 573 
cytosol of late-term and stillbirth placentas representing oxidised RNA (8-hydroxyguanosine) 574 
that is also detected by the antibody. 575 
 576 
Figure 3: Changes in lysosomal distribution in late-term and stillbirth placentas. IHC of 577 
LAMP2 (red), a lysosomal marker showed that lysosomes predominantly localise to the 578 
apical surface of 37-39 week placentas (A), whereas lysosome distribution extends to the 579 
perinuclear and basal surface of syncytiotrophoblast in late-term (B) and stillbirth placentas 580 
(C). Intensity calculation across the syncytiotrophoblast showed that the distribution of 581 
LAMP2 in late-term (n=5, Figure 3F) and unexplained stillbirth placentas (n=4, Figure 3G) 582 
shifts to the perinuclear and basal surface whereas lysosome distribution in 37-39 week 583 
caesarean placentas (n=5, Figure 3D) and vaginal delivery placentas (n=5, Figure 3E) 584 
remained in the apical region of the syncytiotrophoblast. DAPI (blue) staining identifies the 585 
nuclei. In Figures 3D to 3G each coloured line represents results on an individual placenta, 586 
and shows the mean intensity of LAMP2 across the syncytiotrophoblast at 5 random sites per 587 
image (example represented by light green line in 3A, 3B and 3C) for 6 separate images per 588 
placenta. Images were photographed at 100X magnification; scale bar, 20 µm. 589 
 590 
Figure 4: Lipid peroxidation is increased in late-term and stillbirth placentas. 4HNE 591 
(red) immunostaining in 37-39 week (A), late-term (B), and stillbirth (C) placentas. DAPI 592 
(blue) staining identifies nuclei. The intensity of 4HNE is significantly increased in late-term 593 
placentas (D) (p<0.0001, Mann Whitney test) and stillbirth placentas (p=0.0014, Mann 594 
Whitney test). In Figure 4D open circles and filled circles represent 37-39 week caesarean 595 
non-labouring placentas (n=20) and vaginal delivery labouring placentas (n=14) respectively, 596 
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and open squares and filled squares represent late-term labouring caesarean placentas (n=10) 597 
and vaginal delivery placentas (n=18) respectively, while filled triangles represent third 598 
trimester labouring vaginal delivery unexplained stillbirth placentas (n=4). Each point in 4D 599 
represents the mean intensity per unit area for 6 images taken for each individual placenta. 600 
Images were photographed at 100X magnification; scale bar, 20 µm. 601 
 602 
Figure 5: Larger autophagosomes occur in late-term and stillbirth placentas. 603 
Immunofluorescence staining of LC3B (green) in the 37-39 week (A), late-term (B), and 604 
unexplained stillbirth (C) placentas. DAPI (blue) staining indicates the nuclei. 605 
Autophagosome size was quantified using NIS element software and the diameter was 606 
measured at an arbitrary intensity range of 1000-3000, diameter range 0.2-1 µm and 607 
circularity range 0.5-1. Analysis (D) showed that late-term and stillbirth placentas have 608 
significantly larger (p=0.012 and p=0.0019, respectively, Mann Whitney test) 609 
autophagosomes than 37-39 week placentas. In ‘D’ open circles and filled circles represent 610 
37-39 week caesarean non-labouring placentas (n=11) and vaginal delivery labouring 611 
placentas (n=10) respectively, and open squares and filled squares represent late-term 612 
labouring caesarean placentas (n=8) and labouring vaginal delivery placentas (n=15) 613 
respectively, while filled triangles represents unexplained stillbirth placentas (n=4). Each 614 
point in the graph represents the average diameter of LC3B particles in six images taken for 615 
each placenta. Original magnification, 100X; scale bar, 20 µm. Arrow heads indicate 616 
autophagosomes (LC3B positive particles). 617 
 618 
Figure 6: Co-localisation of aldehyde oxidase (AOX1) and 4HNE, and increased 619 
expression of AOX1 mRNA in late-term and stillbirth placentas. Representative dual 620 
labelled fluorescence immunostaining in late-term (A-C) and stillbirth (D-F) placentas 621 
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showed that AOX1 positive particles (green) are co-localized with 4HNE (red). Orange dots 622 
(pointed by arrow heads in C and F) indicate co-localization. Nuclei are stained with DAPI 623 
(blue). Real-time PCR showed that expression of AOX1 mRNA is increased in late-term 624 
(p=0.0097) and stillbirth (p=0.012) placentas compared to early-term placentas (G). Original 625 
magnification100X; scale bar 20 µm.  626 
 627 
Figure 7: Pharmacologic inhibition of 4HNE production. Fluorescence immunostaining 628 
with antibody against 4HNE (red) in serum starved placental explant (A) at time 0 (just 629 
before starvation) (B) at 24 h after culturing in medium containing FBS (control treatment), 630 
(C) at 24 after starvation (culturing in medium without FBS), (D) 24 h after treatment with an 631 
AOX1 inhibitor, raloxifene (RLX) and (E) 24 h after treatment with a membrane estrogen 632 
receptor GPER1 agonist, G1. Intensity calculation showed that the production of 4HNE 633 
(induced by serum starvation) is significantly reduced after treating placental explants with 634 
raloxifene (F) and G1 (G). Data are mean ± S.E.M., *p<0.05 (N=6). Original magnification, 635 
20X; scale bar, 100 µm. DAPI (blue) staining indicates the nuclei.  636 
 637 
Figure 8: Expression of GPER1 in placenta and myometrium, but not in membranes by 638 
IHC, real-time PCR and western-blotting. Fluorescence IHC showed that GPER1 (green) 639 
is localized predominantly in the placental in a section of a term placental roll photographed 640 
at 10X magnification (A). GPER1 (green) was shown to localize in the apical layer of 641 
syncytiotrophoblast of placental villi (B), when photographed at 100X magnification. Scale 642 
bar in ‘A’ and ‘B’ represent 100 µM and 20 µM, respectively. The real-time qPCR data 643 
showed that the mRNA for GPER1 is expressed in higher amounts in term placenta, whereas 644 
amnion, chorion and decidua show very low expression of GPER1 (C). The expression of 645 
mRNA for GPER1 follows the order: decidua<chorion<amnion<placenta. The western blot of 646 
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protein extract from the breast cancer cell line MCF-7, term placenta, myometrium, amnion, 647 
chorion and decidua are presented in ‘D’. Placenta, myometrium and MCF-7 cell lines 648 
expressed higher amounts of GPER1 than amnion, chorion or decidua (D). Western-blotting 649 
data showed that all the tissues expressed glycosylated GPER1 (denoted by ** or by ***) and 650 
non-glycosylated nascent GPER1 (denoted by *). The sypro-ruby stain of the same PVDF 651 
membrane is used as internal loading control (E).  652 
 653 
Supplementary Figure Legends 654 
 655 
Figure S1: Oxidised lipids within autophagosomes of late-term placentas. Representative 656 
dual labelled fluorescence immunostaining showed that LC3B, an autophagosome marker 657 
(green) is co-localised with 4HNE, a marker of lipid peroxidation (red). Orange dots (pointed 658 
by arrow heads in C) indicate the co-localization. DAPI (blue) staining indicates the nuclei. 659 
Original magnifications 100X; scale bar 20 µm. 660 
 661 
Figure S2: Changes in autophagosome size in placental explants cultured in serum 662 
deprived medium. Fluorescence immunostaining with antibody against LC3B (green) in 663 
serum starved placental explant (A) at time 0 (just before starvation) and (B) at 24 h after 664 
starvation. DAPI (blue) staining indicates nuclei. (C) Immunohistochemical analysis showed 665 
that the size of autophagosomes (LC3B positive particles) increased 24 h after serum 666 
starvation compared to 0 h. Data presented as mean ± S.E.M., ***p=0.0002 (N=13). Scale 667 
bar, 20 µM. 668 
 669 
Figure S3: GPER1 regulates lysosomal distribution in placental explants cultured in 670 
serum deprived medium.  Fluorescence immunostaining with antibody against LAMP2 671 
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(red) in serum starved placental explant (A) at time 0 (just before starvation), (B) at 24 h after 672 
culturing in medium containing FBS, (C) at 24 after starvation (culturing in medium without) 673 
FBS, and (D) 24 h after treatment with GPER agonist, G1. DAPI (blue) staining indicates 674 
nuclei. Intensity calculation (E) across the syncytiotrophoblast showed that the distribution of 675 
LAMP2 at 24 h after starvation shifts to the perinuclear and basal surface compared to control 676 
treatment (N=7). Each coloured line in 'E' represents the mean intensity of LAMP2 across the 677 
syncytiotrophoblast at 5 random sites per image for 6 separate images per experiment. In 'F', 678 
each coloured bar indicates mean of the area under the curve (AUC) of the corresponding 679 
coloured line presented in 'E' and statistical differences were calculated. Original 680 
magnifications, 40X; scale bar, 20 µm; error bar, S.E.M.; *p<0.05 (N=7). 681 
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Table 1: Demographic and clinical characteristics of the study subjects 
CC      Characteristic 37-39 Weeks Late-term Stillbirth 
Number of cases 34 28 4 
Gestational ages (weeks) 38.57 ± 0.15 41.46 ± 0.06 32 32.57 39 40.14 
Fetal growth restriction (number of cases) 0 0 No Yes No Yes 
Maternal age (years) 31.03 ± 0.88 28.81 ± 1.15 30.21 ± 2.68 
Vaginal birth (%) 41.20 % 64.30 % 100.00 % 
BMI (kg/m2) at second trimester or at birth 29.10 ± 1.50 28.52 ± 1.10 27.40 ± 2.40 
Ethnicity  
      Caucasian (%) 
 
82.35 % 
 
96.42 % 
 
75.00 % 
Smoker (%) 17.64 % 17.85 % 0.00 % 
Data are presented as (Mean ± SEM) or percentage. BMI, Body Mass Index 
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